
|Videos|December 18, 2020
Safety and efficacy of KPI-121 0.25% for DED treatment
Author(s)David Hutton
Preeya Gupta, MD, discusses the results of a study evaluating the safety and efficacy of KPI-121 0.25% for the treatment of dry eye disease.
Advertisement
Preeya Gupta, MD, discusses the results of a study evaluating the safety and efficacy of KPI-121 0.25% — a nanoparticle ophthalmic suspension of loteprednol etabonate — for the treatment of
Newsletter
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
PRIMAvera study: Central vision improvement with subretinal implant
2
A new treatment round-up for AMD and GA
3
8 things to know about aflibercept 8 mg for retinal vascular disease
4
FDA grants Fast Track Designation to Complement Therapeutics’ CTx001 for geographic atrophy
5












































